#15Metabolic & Frontier
HGH fragment 176-191
C-terminal growth-hormone fragment
Evidence: laboratory-onlyReviewed 2026-07-25
Investigated uses
- No adequately documented human investigated use for the exact catalog identity/formulation was identified; any vendor-promoted goals were excluded from evidence grading.
Mechanism and hypotheses
- HGH fragment 176-191 is the C-terminal portion of growth hormone; AOD-9604 is a closely related analogue with an additional N-terminal tyrosine.
- Hypothesized: Selective lipolytic or weight-loss effects were proposed during historical development but were not established as an approved human therapy.
Human evidence
- No qualifying human trial was identified for the exact HGH fragment 176-191 listing. Human protocols cited for AOD-9604/LAT8881 concern a related but chemically distinct analogue. Limitations: Related-molecule evidence cannot establish efficacy, safety, pharmacokinetics or dose for the exact catalog identity.
Safety highlights
- Unknown or insufficiently characterized for the exact catalog product.
- Identity, purity, sterility, endotoxin, aggregation, immunogenicity, concentration and route-specific risks are not adequately characterized.
Regulatory context
No FDA-approved product matching the exact catalog presentation was identified in this review.
Sources used for this entry
- PubMed search: HGH fragment 176-191 — PubMed
- Drugs@FDA database — U.S. Food and Drug Administration
- EMA medicines search — European Medicines Agency
- NCT03865953: Oral LAT8881 in neuropathic pain — ClinicalTrials.gov
- NCT05298306: Intravenous LAT8881 proof-of-concept — ClinicalTrials.gov